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Abstract
Familial hypercholesterolemia (FH) is the most common genetic disorder in the 
world. It is characterized by increased level of total cholesterol (TC), low-density 
lipoproteins (LDL-C) since childhood. The diagnosis and initiation of therapy 
are optimal in childhood before complications (aortic stenosis, atherosclerotic 
changes in the arterial walls) appear. The initiation of lipid-lowering therapy in FH 
since childhood is important to reduce the cumulative effect of LDL-C, to increase 
patient’s life expectancy. Statins are recommended as first-line drugs for treatment 
with monitoring of the recommended clinical, biochemical markers under the 
supervision of a physician. However, due to limited experience, there are differing 
opinions among clinicians regarding the age of initiation of lipid-lowering therapy. 
This review is an attempt to critically study the available data from the world litera-
ture concerning the use of statins in children with FH, their effectiveness, safety. It 
is important to determine the endpoints for determining the effectiveness of statins, 
such as lowering LDL-C, assessing the thickness of the intima-media complex. The 
frequency of occurrence of possible side effects in children is considered - diabetes 
mellitus, hepatotoxicity, muscle pain and others. There is a need to continue ran-
domized trials to prove the lifelong benefit of low LDL-C in patients with FH.
Keywords: children, familial hypercholesterolemia, total cholesterol, low density 
lipoprotein efficacy, treatment, statins, side effects
1. Introduction
Hypercholesterolemia occupies an important place among the factors of cardio-
vascular mortality [1]. It is known that the level of lipids in 40–60% of cases is due 
to genetic reasons [2]. Familial hypercholesterolemia is one of the most common 
hereditary diseases: its prevalence is 1: 200–1: 500 in the general population [3]. 
The estimated number of people with a heterozygous form of the disease in Russia 
should be about 1 million [4]. Despite the high urgency of early detection of the 
disease, in our country it is diagnosed in less than 1% of the expected number of 
patients. Diagnosis and initiation of therapy for the disease in childhood are consid-
ered optimal before complications such as aortic stenosis, atherosclerotic changes in 
the arterial walls appear. Statins are recommended for treatment as first-line drugs, 
but experience with their use in children is limited and requires special analysis.
Statins are 3-hydroxy-3-methyl coenzyme A reductase inhibitors that limit the 
rate of endogenous cholesterol synthesis. This leads to a decrease in the content of 
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intracellular cholesterol and the level of circulating LDL-C in the blood. In addition 
to the lipid-lowering effect, statins affect atherosclerotic plaque (reduce its size, 
stabilize the surface, thereby reducing the risk of rupture and ulceration), as well as 
inflammatory factors and endothelial function (pleiotropic effects) [5]. The main 
goal of prescribing statins in familial hypercholesterolemia is to reduce the risk 
and rate of development of atherosclerosis and coronary heart disease in order to 
delay the onset of cardiovascular accidents as much as possible. It should be noted 
that the use of statins among the adult population, as a rule, is not in doubt, while 
the pharmacotherapy of hypercholesterolemia in pediatrics raises questions from 
doctors and parents regarding its effectiveness, long-term prospects and possible 
complications.
2. Use of statins in world wild practice
The effectiveness of statins in familial hypercholesterolemia can be judged 
primarily by the degree of decrease in serum LDL cholesterol levels. The European 
and International Atherosclerosis Societies stated that, based on the available data, 
the hypothesis of atherogenesis associated with high LDL-C levels is no longer a 
hypothesis and can be considered a proven fact [6]. Randomized studies show that 
the effect of LDL-C on the development of atherosclerotic vascular disease is deter-
mined not only by the absolute level of LDL cholesterol, but also by its cumulative 
effect on the arterial wall [6–8]. It is known that the cumulative effect of LDL-C 
increases with age and is 160 mmol in a healthy person by the age of 55. In the 
absence of treatment, patients with familial hypercholesterolemia reach this value 
from the age of 35. It has been shown that starting statin therapy from 18 years of 
age allows this cumulative load to be postponed to 48 years of age. When statins are 
taken from the age of 10, the accumulation of LDL-C of 160 mmol is achieved only 
by the age of 53, which is close to the indicators of healthy people [9].
Demonstrated clinically significant reduction in LDL cholesterol levels in 
children with familial hypercholesterolemia taking statins compared with children 
receiving placebo. Moreover, the degree of reduction varied depending on the 
dose and the drug used. In the work of S.B. Clauss et al. (2005) [10] described the 
experience of using lovastatin in girls with familial hypercholesterolemia at a dose of 
20–40 mg/day for 24 weeks. The authors concluded that in the lovastatin group there 
was a significant decrease in LDL cholesterol from baseline by 23–27%, total cho-
lesterol by 17–22%, and apolipoprotein B by 20–23%. In another study, pravastatin 
versus placebo in children with familial hypercholesterolemia younger than 14 years 
old at a dose of 20 mg/day and over 14 years old - at a dose of 40 mg/day with a 
duration of therapy of 104 weeks, the decrease in LDL cholesterol levels reached 
24.1% [11]. A number of works have been devoted to the experience of using atorv-
astatin in childhood. It was shown that the appointment of atorvastatin at a dose of 
20–40 mg/day compared with placebo for 6–48 months led to a significant decrease 
in LDL cholesterol by an average of 32–39%, total cholesterol by 32%, triglycerides 
by 12% and apolipoprotein B by 34% [12–14]. It should be noted that in one of the 
studies, a statistically significant increase in the level of HDL cholesterol by 2.8% 
was stated [12]. In a study by H.J. Avis et al. (2010) [15], who studied the efficacy of 
rosuvastatin in children with familial hypercholesterolemia compared with placebo, 
showed a decrease in LDL cholesterol, total cholesterol and apolipoprotein B levels 
for all three doses (5 mg, 10 mg and 20 mg) with a duration of 12 week Thus, in 
general, the results of studies evaluating the effects of statins in familial hypercho-
lesterolemia demonstrate the effectiveness of statins in lowering LDL cholesterol 
and total cholesterol levels in children.
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3. Effect of statins on the thickness of the intima-media complex
Another important endpoint for determining the effectiveness of statins is the 
thickness of the intima-media complex, a clinically significant marker of cardiovas-
cular disease. It is noted that the thickness of the intima-media complex in children 
depends on age, gender and LDL cholesterol level [16]. In children with familial 
hypercholesterolemia, a much faster increase in this parameter with age was found 
than in healthy brothers and sisters [17]. Currently, there is a number of studies 
demonstrating the effect of statins on reducing the thickness of the intima-media 
complex. M.J. Braamskamp et al. [18] found that in the case of initiation of statin 
therapy in familial hypercholesterolemia from the age of 12 years, the thickening 
of the intima-media complex in children occurs more slowly than in peers with 
familial hypercholesterolemia who do not take statins. The authors concluded that 
early initiation of statin treatment can delay atherosclerotic changes in the vessels 
in adolescents and young adults [18]. Statin therapy also has a positive effect on 
markers of atherosclerosis such as flow-dependent vasodilation. In a study by S. De 
Jongh et al. (2002) [19], it was found that against the background of 28-week treat-
ment with simvastatin, the flow-dependent vasodilation significantly improved 
by an average of 4% in children with heterozygous familial hypercholesterolemia 
compared with that in healthy peers who received placebo.
4. Long-term studies of the effectiveness of statins in childhood
The need for long-term studies to assess the effectiveness of statins in childhood 
has been repeatedly emphasized. In October 2019, a group of scientists published 
the results of the longest to date follow-up of children with familial hypercholes-
terolemia taking statins [8]. 214 patients with this disease and their 95 healthy 
brothers and sisters were under observation for 20 years. It was found that patients 
taking statins did not significantly differ from their healthy siblings in terms of 
an increase in the thickness of the intima-media complex. At the same time, the 
incidence of cardiovascular diseases and mortality from them at the age of 39 years 
among patients with familial hypercholesterolemia was lower than among their 
parents suffering from this disease, and amounted to 1% versus 26% and 0 versus 
7%, respectively. These studies make it possible to substantiate the need for the use 
of statins for the primary prevention of complications and increase life expectancy 
in children with familial hypercholesterolemia. The effectiveness of treatment 
depends on the dose of drugs and the age of initiation of therapy. The authors of 
these and a number of other clinical studies emphasize the need to start statin 
therapy at the age of 8–10 years [9, 20–23].
5. Features of statins usage in children with FH in clinical practice
In clinical practice, along with an increase in the frequency of statin use, their 
side effects are increasingly the subject of research. In adults, statin-related side 
effects include elevated liver transaminases, creatine kinase, and rhabdomyolysis 
[24]. The main concerns in the pediatric population are the risk of developing 
myalgias, as well as the possible effect of statins on liver function [13, 19], choles-
terol-dependent production of steroid hormones in the gonads and adrenal glands 
[24] and energy metabolism [25], as well as the child’s growth [26].
In a number of studies, when using statins in children with familial hypercholes-
terolemia, it is noted the occurrence of muscle pain: when taking pitavastatin, they 
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developed within 3 months in 9.3% cases [18], and when taking pravastatin and 
atorvasttin - for 48 months in 12.2% of cases [12]. This prevalence of side effects 
in the form of muscle damage is higher than in adults, who experience myalgia in 
only 1.5–5% of cases [27]. In this regard, the authors concluded that most of the 
presented cases of side effects of statins on skeletal muscles in children may not 
be myalgias directly related to taking statins, but “growing pains” and subjective 
feelings of the child. A meta-analysis of 6 studies evaluating the efficacy and safety 
of statins in children with familial hypercholesterolemia with a total of 798 study 
participants with statin treatment durations from 12 to 104 weeks did not reveal a 
statistically significant increase in the number of side effects, including myalgias, 
when prescribing statins compared with placebo [28]. The European Society of 
Atherosclerosis recommends measuring the level of creatine phosphokinase (CPK) 
before treatment and 1–3 months after the start of statin therapy [29] in order to 
control the possible occurrence of myalgias.
The studied side effects, in respect of which remain alert, is hepatotoxicity. 
Several studies with a total of 943 children with familial hypercholesterolemia 
taking statins have examined the effect of statins on liver function [30, 31]. The 
authors emphasize the absence of significant differences in the incidence of viola-
tions of the activity of hepatic transaminases in treatment with statins and taking 
placebo. This confirms the good tolerability of the drugs. The European Society 
of Atherosclerosis recommends measuring the levels of alanine and aspartate 
aminotransferases (ALT and AST) before starting statin therapy, and then every 
3 months during treatment if there is a history of liver disease or an increase in 
the level of hepatic transaminases by more than 3 times from the upper limit of 
normal [32].
Other discussed potential side effects of statins include puberty disorders. 
Randomized studies evaluating the efficacy and safety of statins in children with 
familial hypercholesterolemia found no signs of impaired puberty when pravas-
tatin was used at a dose of 20–40 mg/day for 104 weeks [9] and pitavastatin at 
a dose of 1 mg/2 mg/4 mg/days for 12 weeks [18]. S.B. Clauss (2005) [10] in his 
article expressed theoretical concerns regarding the use of statins in adolescent girls 
with potential effects on pituitary hormones (luteinizing hormone and follicle-
stimulating hormone), menstrual cycle and physical development. However, in a 
24-week study in which adolescent girls with familial hypercholesterolemia took 
lovastatin 20–40 mg/day, these side effects were not reported [33]. A number of 
researchers have also demonstrated the safety of using drugs (pravastatin, atorvas-
tatin, rosuvastatin) in children over a similar 2-year period [10, 19, 34].
In recent years, the likelihood of an increase in the risk of developing type 2 
diabetes mellitus with prolonged use of statins in adults in the general popula-
tion has been actively discussed. In a study by J. Besseling et al. (2015), including 
more than 63 thousand patients with familial hypercholesterolemia taking statins, 
showed that the prevalence of type 2 diabetes in this group was significantly lower 
than that of their relatives (1.75% versus 2.93%; p < 0.05) [35]. A 10-year prospec-
tive follow-up of 194 children with familial hypercholesterolemia receiving statins 
revealed one new case of type 2 diabetes mellitus without significant differences 
in morbidity in their 83 siblings without familial hypercholesterolemia [36]. N. 
Joyce et al. (2017) [37] also showed no significant differences in the incidence of 
type 2 diabetes mellitus among children taking statins compared with children not 
receiving drugs in this group.
Thus, it should be noted that the occurrence of side effects when using statins 
in children cannot be completely ruled out. However, the analysis of studies carried 
out in this direction emphasizes the low probability of their occurrence. The key 
when prescribing statins to a child with familial hypercholesterolemia is careful 
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monitoring of complaints, clinical condition, and a number of biochemical markers 
in the blood (ALT, AST, CPK). It is also necessary to monitor the patient’s condition 
with prompt correction of the drug and the dose received by the child.
Separate sections devoted to the use of statins in childhood are presented in the 
most frequently cited clinical guidelines for the diagnosis and treatment of dyslip-
idemia: American [38], Japanese [20] and Australian [21]. In 2019, the results of a 
study conducted in 8 European countries (Norway, Great Britain, Czech Republic, 
Portugal, Greece, Austria, the Netherlands, Belgium) were published, which 
compared the tactics and results of treatment of familial hypercholesterolemia in 
a total sample of 3064 children. It has been shown that the proportion of children 
taking statins increases with age and by the age of 15, already 79% of patients in 
these countries are taking statins [39]. The goals for children over 10 years of age are 
to achieve LDL cholesterol <3.5 mmol/L (<135 mg/dL), at a younger age - to reduce 
this indicator by ≥50%. In the United States and Europe, simvastatin, lovastatin, 
atorvastatin, pravastatin, fluvastatin, and rosuvastatin are approved for use in 
children with familial hypercholesterolemia. In the United States, all of these statins 
are approved from the age of 10, with the exception of pravastatin, which is recom-
mended from the age of 8. In Europe, rosuvastatin is approved from 6 years old, in 
Australia atorvastatin is approved in children from 6 years old. It is recommended 
to start statin therapy with low doses and increase it until the set goals are achieved 
[29] with a possible increase to the maximum admissible dose in childhood estab-
lished for each of the drugs. This dose is 20 mg for pravastatin for children under 
13 years of age and 40 mg for children under 18; for rosuvastatin - 10 mg up to 
9 years and 20 mg - up to 18 years; for atorvastatin - 40 mg regardless of age [12].
The results of recent randomized studies on the efficacy and safety of statins in 
children with familial hypercholesterolemia formed the basis for the joint recom-
mendations of the European Society of Cardiology and the European Society of 
Atherosclerosis [29]. In 2018, Russian guidelines for the diagnosis and treatment of 
familial hypercholesterolemia were published [40]. These recommendations serve 
as the main document in the work of a pediatric cardiologist and pediatrician when 
monitoring children with familial hypercholesterolemia. According to these recom-
mendations, statin therapy should be considered in children aged 8–10 years with 
heterozygous disease.
Particular vigilance should be shown in relation to children with a homozy-
gous form of familial hypercholesterolemia, in which lipid-lowering therapy 
should be started as early as possible, immediately after the diagnosis. It is 
recommended to prescribe therapy with maximum tolerated doses of statins in 
combination with other lipid-lowering drugs in order to maximize the reduction 
of LDL cholesterol [40].
6. Conclusions
Thus, the initiation of lipid-lowering therapy in familial hypercholesterolemia 
from childhood is of great importance for reducing the cumulative effect of LDL 
cholesterol and increasing the patient’s life expectancy. When answering ques-
tions regarding the treatment of children with dyslipidemia, one should take 
into account the compelling reasons to follow international recommendations 
and use statins for familial hypercholesterolemia from the age of 8–10 years, 
with monitoring of the recommended clinical and biochemical markers under 
the supervision of a physician. There is currently a need to continue randomized 
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